Recent Updates
Recently added Catalysts
MLTX Negative Sentiment Score: 15/100

MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating MoonLake Immunotherapeutics for potential violations of federal securities laws following a significant decline in share value. On September 29, 2025, the company reported that its VELA-2 trial had failed to achieve statistical significance, resulting in an 89.9% drop in stock price. The law firm invites affected investors to discuss their legal options as the situation develops, underlining serious concerns regarding the company's business practices.

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake stock plummeted 89.9% following the announcement of the failed VELA-2 trial.
  • The investigation into MoonLake suggests potential violations of federal securities laws.
  • Investors are encouraged to consider their legal rights due to significant losses.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Moon Lake and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ:MLTX) on behalf of MoonLake stockholders. Our investigation concerns whether MoonLake has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On September 29, 2025, before the market opened, MoonLake Immunotherapeutics filed with the SEC a current report on Form 8-K. Attached to the current report was a press release which stated that, in MoonLake’s VELA-2 trial, “intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy[.]”
On this news, MoonLake stock plummeted 89.9% on September 29, 2025.
If you purchased or otherwise acquired MoonLake shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

MoonLake Immunotherapeutics
Bragar Eagel & Squire

Frequently Asked Questions

What should MoonLake investors do if they suffered losses?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire to discuss options.

Why is Bragar Eagel & Squire investigating MoonLake?

They are investigating potential violations of federal securities laws by MoonLake.

What happened to MoonLake stock on September 29, 2025?

MoonLake stock dropped 89.9% due to an announcement about the VELA-2 trial.

How can I contact Bragar Eagel & Squire for inquiries?

You can email investigations@bespc.com or call (212) 355-4648 for inquiries.

Is there a cost to consult with Bragar Eagel & Squire?

No, there is no cost or obligation to consult regarding your rights.

Last updated: Oct 7, 2025